Dendritic Cell Vaccination During Lymphoid Reconstruction
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients
are randomized to 1 of 2 treatment arms.
The purpose of this study is to find out what side effects are caused in this study and
whether Fludarabine with the dendritic cell vaccine (DC vaccine) can increase the ability of
the immune system to recognize melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute